Treatment of comorbidities of chronic daily headache

被引:9
作者
Ashina, Sait [1 ]
Lipton, Richard B. [1 ]
Bigal, Marcelo E. [1 ]
机构
[1] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA
关键词
D O I
10.1007/s11940-008-0005-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of chronic daily headaches should focus not only on establishing an effective plan for pain therapy but also on addressing factors that may diminish progression from episodic headache toward chronic daily headache. These measures may translate into better treatment efficacy and satisfaction, as well as decrease the headache burden. Because episodic migraine progresses to chronic daily headache in some (not most) individuals, research will increasingly focus on identifying factors associated with progression, such as specific genetic and environmental risk factors, including comorbidities. Ultimately, the assessment of the migraine patient will include an evaluation of risk factors for progression. In addition to the symptom profile, evaluation will increasingly focus on comorbidities, ictal and interictal functional consequences of migraine, health-related quality of life, treatment needs, and treatment preferences. Estimation of the risk of progression will incorporate assessments of comorbidity, exposures, and eventually biomarkers. Those with high risk of progression will be more aggressively treated, not just to relieve current pain and disability but to prevent progression. Therefore, treatment will focus on decreasing current burden and preventing future burden.
引用
收藏
页码:36 / 43
页数:8
相关论文
共 63 条
  • [1] Does chronic daily headache arise de novo in association with regular use of analgesics?
    Bahra, A
    Walsh, M
    Menon, S
    Goadsby, PJ
    [J]. HEADACHE, 2003, 43 (03): : 179 - 190
  • [2] Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment
    Berilgen, MS
    Bulut, S
    Gonen, M
    Tekatas, A
    Dag, E
    Mungen, B
    [J]. CEPHALALGIA, 2005, 25 (11) : 1048 - 1053
  • [3] Obesity, migraine, and chronic migraine - Possible mechanisms of interaction
    Bigal, Marcelo E.
    Lipton, Richard B.
    Holland, Philip R.
    Goadsby, Peter J.
    [J]. NEUROLOGY, 2007, 68 (21) : 1851 - 1861
  • [4] Obesity is a risk factor for transformed migraine but not chronic tension-type headache
    Bigal, Marcelo E.
    Lipton, Richard B.
    [J]. NEUROLOGY, 2006, 67 (02) : 252 - 257
  • [5] Chronic daily headache: Identification of factors associated with induction and transformation
    Bigal, ME
    Sheftell, FD
    Rapoport, AM
    Tepper, SJ
    Lipton, RB
    [J]. HEADACHE, 2002, 42 (07): : 575 - 581
  • [6] Obesity and migraine - A population study
    Bigal, ME
    Liberman, JN
    Lipton, RB
    [J]. NEUROLOGY, 2006, 66 (04) : 545 - 550
  • [7] Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes
    Bigal, ME
    Rapoport, AM
    Sheftell, FD
    Tepper, SJ
    Lipton, RB
    [J]. CEPHALALGIA, 2004, 24 (06) : 483 - 490
  • [8] Amitriptyline and dexamethasone combined treatment in drug-induced headache
    Bonuccelli, U
    Nuti, A
    Lucetti, C
    Pavese, N
    DellAgnello, G
    Muratorio, A
    [J]. CEPHALALGIA, 1996, 16 (03) : 197 - 200
  • [9] Topiramate for migraine prevention - A randomized controlled trial
    Brandes, JL
    Saper, JR
    Diamond, M
    Couch, JR
    Lewis, DW
    Schmitt, J
    Neto, W
    Schwabe, S
    Jacobs, D
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (08): : 965 - 973
  • [10] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    [J]. OBESITY RESEARCH, 1996, 4 (03): : 263 - 270